Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies

References

• Ito T, Igarashi H, Jensen RT. Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol. 2012;26:737–753.
   PubMed Web of Science ®Google Scholar
• Jensen RT, Norton JA, Oberg K. Neuroendocrine tumors. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran’s gastrointestinal and liver diseases. 10th ed. Philadelphia: Elsevier Saunders. Vol. 16 A.D., 2016. p. 501–541.
   Google Scholar
• Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–3072.
   PubMed Web of Science ®Google Scholar
• Fraenkel M, Kim MK, Faggiano A, et al. Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26:691–703.
   PubMed Web of Science ®Google Scholar
• Ito T, Igarashi H, Nakamura K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol. 2015;50:58–64.
   PubMed Web of Science ®Google Scholar
• Ito T, Igarashi H, Jensen RT. Zollinger-Ellison syndrome: recent advances and controversies. Curr Opin Gastroenterol. 2013;29:650–661.
   PubMed Web of Science ®Google Scholar
• Fishbeyn VA, Norton JA, Benya RV, et al. Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: the best approach. Ann Intern Med. 1993;119:199–206.
   PubMed Web of Science ®Google Scholar
• Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103:153–171.
   PubMed Web of Science ®Google Scholar
• Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–4663.
   PubMed Web of Science ®Google Scholar
• Caplin ME, Pavel M, Cwikla J, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–233.
   PubMed Web of Science ®Google Scholar
• Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968–977.
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–523.
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–513.
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Wolin EM, Chasen B, et al. NETTER-1 phase III: progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroeneodcrine tumors treated with 177-Lu-Dotatate. J Clin Oncol. 2016;34(4 supplement):194. Ref Type: Abstract.
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, De Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–2130.
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, Krenning EP. Peptide receptor radionuclide therapy in the treatment of neuroendocrine tumors. Hematol Oncol Clin North Am. 2016;30:179–191.
   PubMed Web of Science ®Google Scholar
• Ito T, Igarashi H, Jensen RT. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol. 2012;47:941–960.
   PubMed Web of Science ®Google Scholar
• Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer. 2015;121:1172–1186.
   PubMed Web of Science ®Google Scholar
• Frilling A, Al-Nahhas A, Clift AK. Transplantation and debulking procedures for neuroendocrine tumors. Front Horm Res. 2015;44:164–176.
   PubMed Web of Science ®Google Scholar
• De Baere T, Deschamps F, Tselikas L, et al. GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs. Eur J Endocrinol. 2015;172:R151–R166.
   PubMed Web of Science ®Google Scholar
• Gupta S. Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases. Semin Intervent Radiol. 2013;30:28–38.
   PubMed Web of Science ®Google Scholar
• Kennedy AS. Hepatic-directed therapies in patients with neuroendocrine tumors. Hematol Oncol Clin North Am. 2016;30:193–207.
   PubMed Web of Science ®Google Scholar
• Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42:557–577.
   PubMed Web of Science ®Google Scholar
• Pavel M, O’Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial Neuroendocrine Neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172–185.
   PubMed Web of Science ®Google Scholar
• Singh S, Asa SL, Dey C, et al. Diagnosis and management of gastrointestinal neuroendocrine tumors: an evidence-based Canadian consensus. Cancer Treat Rev. 2016;47:32–45.
   PubMed Web of Science ®Google Scholar
• Niederle B, Pape UF, Costa F, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 2016;103:125–138.
   PubMed Web of Science ®Google Scholar
• Jensen RT, Niederle B, Mitry E, et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology. 2006;84:173–182.
   PubMed Web of Science ®Google Scholar
• Jensen RT, Cadiot G, Brandi ML, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95:98–119.
   PubMed Web of Science ®Google Scholar
• Glanemann M, Shi B, Liang F, et al. Surgical strategies for treatment of malignant pancreatic tumors: extended, standard or local surgery? World J Surg Oncol. 2008;6:123.
   PubMed Web of Science ®Google Scholar
• Maton PN, Gardner JD, Jensen RT. Cushing’s syndrome in patients with Zollinger-Ellison syndrome. N Engl J Med. 1986;315:1–5.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Federspiel B, Bardram L. A neuroendocrine tumor syndrome from cholecystokinin secretion. N Engl J Med. 2013;368:1165–1166.
   PubMed Web of Science ®Google Scholar
• Ito T, Igarashi H, Uehara H, et al. Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore). 2013;92:135–181.
   PubMed Web of Science ®Google Scholar
• Ito T, Igarashi H, Uehara H, et al. Pharmacotherapy of Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2013;14:307–321.
   PubMed Web of Science ®Google Scholar
• Ellison EH, Wilson SD. The Zollinger-Ellison syndrome: re-appraisal and evaluation of 260 registered cases. Ann Surg. 1964;160:512–530.
   PubMed Web of Science ®Google Scholar
• Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine (Baltimore). 2000;79:379–411.
   PubMed Web of Science ®Google Scholar
• Horsch D, Ezziddin S, Haug A, et al. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: a multi-institutional registry study with prospective follow-up. Eur J Cancer. 2016;58:41–51.
   PubMed Web of Science ®Google Scholar
• Norton JA, Alexander HR, Fraker DL, et al. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases or survival in patients with Zollinger-Ellison syndrome (ZES)? Ann Surg. 2004;239:617–626.
   PubMed Web of Science ®Google Scholar
• Bainbridge HE, Larbi E, Middleton G. Symptomatic control of neuroendocrine tumours with everolimus. Horm Cancer. 2015;6:254–259.
   PubMed Web of Science ®Google Scholar
• Bernard V, Lombard-Bohas C, Taquet MC, et al. Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. Eur J Endocrinol. 2013;168:665–674.
   PubMed Web of Science ®Google Scholar
• Fiebrich HB, Siemerink EJ, Brouwers AH, et al. Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. Oncologist. 2011;16:783–787.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med. 2009;360:195–197.
   PubMed Web of Science ®Google Scholar
• Asayama M, Yamada-Murano T, Hara H, et al. Everolimus dramatically improves glycemic control in unresectable metastatic insulinoma: a case report. Jpn J Clin Oncol. 2014;44:186–190.
   PubMed Web of Science ®Google Scholar
• Baratelli C, Brizzi MP, Tampellini M, et al. Intermittent everolimus administration for malignant insulinoma. Endocrinol Diabetes Metab Case Rep. 2014;2014:140047.
   PubMedGoogle Scholar
• Bozkirli E, Bakiner O, Abali H, et al. A case of inoperable malignant insulinoma with resistant hypoglycemia who experienced the most significant clinical improvement with everolimus. Case Rep Endocrinol. 2013;2013:636175.
   PubMedGoogle Scholar
• Cuesta Hernandez M, Gomez Hoyos E, Marcuello Foncillas C, et al. Advanced malignant insulinoma. Everolimus response and toxicity. Endocrinol Nutr. 2014;61:e1–e3.
   Google Scholar
• Thomas NJ, Brooke AM, Besser GM. Long-term maintenance of normoglycaemia using everolimus in a patient with disseminated insulinoma and severe hypoglycaemia. Clin Endocrinol (Oxf). 2013;78:799–800.
   PubMed Web of Science ®Google Scholar
• Bourcier ME, Sherrod A, DiGuardo M, et al. Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases. J Clin Endocrinol Metab. 2009;94:3157–3162.
   PubMed Web of Science ®Google Scholar
• Raymond E, Hobday T, Castellano D, et al. Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Cancer Metastasis Rev. 2011;30(Suppl 1):19–26.
   PubMed Web of Science ®Google Scholar
• De Mestier L, Walter T, Brixi H, et al. Sunitinib achieved fast and sustained control of VIPoma symptoms. Eur J Endocrinol. 2015;172:K1–K3.
   Google Scholar
• Chen J, Wang C, Han J, et al. Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma. Expert Rev Anticancer Ther. 2013;13:737–743.
   PubMed Web of Science ®Google Scholar
• Bourcier ME, Vinik AI. Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma). Pancreas. 2013;42:348–352.
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, Kam BL, Van Essen M, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17:R53–R73.
   PubMed Web of Science ®Google Scholar
• Baumann T, Rottenburger C, Nicolas G, et al. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging. Best Pract Res Clin Endocrinol Metab. 2016;30:45–57.
   PubMed Web of Science ®Google Scholar
• Strosberg J, Wolin E, Chasen B, et al. 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumors: results of the Phase III NETTER-1 Trial. In: Abstracts of 2015 NANETs meeting (C39). 2015. Ref Type: Abstract.
   Google Scholar
• Van Schaik E, Van Vliet EI, Feelders RA, et al. Improved control of severe hypoglycemia in patients with malignant insulinomas by Peptide receptor radionuclide therapy. J Clin Endocrinol Metab. 2011;96:3381–3389.
   PubMed Web of Science ®Google Scholar
• Koffas A, Popat R, Dimitriou N, et al. Efficacy of Lutetium-177 DOTA octreotate peptide receptor radionuclide therapy in patients with advanced neruoendocrine tumors and carcinoid syndrome refractory to somatostatin analogues. In: Abstract book of 13th Annual ENET Conference; 2016 Mar 9–11; Barcelona (Spain); 2016. p. 228. Ref Type: Abstract.
   Google Scholar
• Seregni E, Maccauro M, Coliva A, et al. Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging. 2010;54:84–91.
   PubMed Web of Science ®Google Scholar
• Chandra P, Yarandi SS, Khazai N, et al. Management of intractable hypoglycemia with Yttirum-90 radioembolization in a patient with malignant insulinoma. Am J Med Sci. 2010;340:414–417.
   PubMed Web of Science ®Google Scholar
• Costa R, Costa R, Bacchi CE, et al. Metastatic insulinoma managed with radiolabeled somatostatin analog. Case Rep Endocrinol. 2013;2013:252159.
   PubMedGoogle Scholar
• Fischbach J, Gut P, Matysiak-Grzes M, et al. Combined octreotide and peptide receptor radionuclide therapy ((90)Y-DOTA-TATE) in case of malignant insulinoma. Neuro Endocrinol Lett. 2012;33:273–278.
   PubMed Web of Science ®Google Scholar
• Makis W, McCann K, McEwan AJ. Metastatic insulinoma pancreatic neuroendocrine tumor treated with 177Lu-DOTATATE induction and maintenance peptide receptor radionuclide therapy: a suggested protocol. Clin Nucl Med. 2016;41:53–54.
   PubMed Web of Science ®Google Scholar
• Makis W, McCann K, Riauka TA, et al. Ectopic corticotropin-producing neuroendocrine tumor of the pancreas treated with 177Lu DOTATATE induction and maintenance peptide receptor radionuclide therapy. Clin Nucl Med. 2016;41:50–52.
   PubMed Web of Science ®Google Scholar
• Makis W, McCann K, Riauka TA, et al. Glucagonoma pancreatic neuroendocrine tumor treated with 177Lu DOTATATE induction and maintenance peptide receptor radionuclide therapy. Clin Nucl Med. 2015;40:877–879.
   PubMed Web of Science ®Google Scholar
• Makis W, McCann K, Riauka TA, et al. Resolution of hyperreninemia, secondary hyperaldosteronism, and hypokalemia with 177Lu-DOTATATE induction and maintenance peptide receptor radionuclide therapy in a patient with pancreatic neuroendocrine tumor. Clin Nucl Med. 2015;40:880–884.
   PubMed Web of Science ®Google Scholar
• Davi MV, Bodei L, Ferdeghini M, et al. Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposal. Endocr Pract. 2008;14:213–218.
   PubMedGoogle Scholar
• Sowa-Staszczak A, Pach D, Kunikowska J, et al. Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours. Endokrynol Pol. 2011;62:392–400.
   PubMed Web of Science ®Google Scholar
• Nieman LK. Cushing’s syndrome: update on signs, symptoms and biochemical screening. Eur J Endocrinol. 2015;173:M33–M38.
   PubMed Web of Science ®Google Scholar
• Del Prete M, Fiore F, Modica R, et al. Hepatic arterial embolization in patients with neuroendocrine tumors. J Exp Clin Cancer Res. 2014;33:43.
   PubMed Web of Science ®Google Scholar
• Kennedy A, Bester L, Salem R, et al. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-liver-metastases consensus conference. HPB (Oxford). 2015;17:29–37.
   PubMed Web of Science ®Google Scholar
• Yang TX, Chua TC, Morris DL. Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases - a systematic review. Surg Oncol. 2012;21:299–308.
   PubMed Web of Science ®Google Scholar
• Fiore F, Del Prete M, Franco R, et al. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 2014;47:177–182.
   PubMed Web of Science ®Google Scholar
• Bloomston M, Al-Saif O, Klemanski D, et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg. 2007;11:264–271.
   PubMed Web of Science ®Google Scholar
• Kyriacou A, Mansoor W, Lawrance J, et al. Intractable hypoglycaemia in a patient with advanced carcinoid syndrome successfully treated with hepatic embolization. Hormones (Athens). 2015;15:118–121.
   Google Scholar
• Maiza JC, Vezzosi D, Grunenwald S, et al. Treatment with somatostatin analogs and chemoembolization of liver metastases for severe hypoglycemia in malignant insulinomas. J Endocrinol Invest. 2011;34:e253–e258.
   Web of Science ®Google Scholar
• Moscetti L, Saltarelli R, Giuliani R, et al. Intra-arterial liver chemotherapy and hormone therapy in malignant insulinoma: case report and review of the literature. Tumori. 2000;86:475–479.
   PubMed Web of Science ®Google Scholar
• Muro S, Nasu J, Harada R, et al. Prompt resolution of hypoglycemia by hepatic transarterial embolization for malignant insulinoma with multiple liver metastases. Acta Med Okayama. 2014;68:303–306.
   PubMedGoogle Scholar
• Pericleous M, Caplin ME, Tsochatzis E, et al. Hepatic artery embolization in advanced neuroendocrine tumors: efficacy and long-term outcomes. Asia Pac J Clin Oncol. 2016;12:61–69.
   PubMed Web of Science ®Google Scholar
• Yarmohammadi H, Erinjeri JP, Brown KT. Embolization of metastatic neuroendocrine tumor resulting in clinical manifestations of syndrome of inappropriate secretion of antidiuretic hormone. J Vasc Interv Radiol. 2015;26:533–537.
   PubMed Web of Science ®Google Scholar
• Harring TR, Nguyen NT, Goss JA, et al. Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review. Int J Hepatol. 2011;2011:1–11.
   Google Scholar
• Eriksson J, Stalberg P, Nilsson A, et al. Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg. 2008;32:930–938.
   PubMed Web of Science ®Google Scholar
• Mazzaglia PJ, Berber E, Milas M, et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery. 2007;142:10–19.
   PubMed Web of Science ®Google Scholar
• Karabulut K, Akyildiz HY, Lance C, et al. Multimodality treatment of neuroendocrine liver metastases. Surgery. 2011;150:316–325.
   PubMed Web of Science ®Google Scholar
• Gillams A, Cassoni A, Conway G, et al. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging. 2005;30:435–441.
   PubMedGoogle Scholar
• Armellini E, Crino SF, Ballare M, et al. Endoscopic ultrasound-guided ethanol ablation of pancreatic neuroendocrine tumours: A case study and literature review. World J Gastrointest Endosc. 2016;8:192–197.
   PubMed Web of Science ®Google Scholar
• Deprez PH, Claessens A, Borbath I, et al. Successful endoscopic ultrasound-guided ethanol ablation of a sporadic insulinoma. Acta Gastroenterol Belg. 2008;71:333–337.
   PubMed Web of Science ®Google Scholar
• Jurgensen C, Schuppan D, Neser F, et al. EUS-guided alcohol ablation of an insulinoma. Gastrointest Endosc. 2006;63:1059–1062.
   PubMed Web of Science ®Google Scholar
• Lakhtakia S, Ramchandani M, Galasso D, et al. EUS-guided radiofrequency ablation for management of pancreatic insulinoma by using a novel needle electrode (with videos). Gastrointest Endosc. 2016;83:234–239.
   PubMed Web of Science ®Google Scholar
• Lee MJ, Jung CH, Jang JE, et al. Successful endoscopic ultrasound-guided ethanol ablation of multiple insulinomas accompanied with multiple endocrine neoplasia type 1. Intern Med J. 2013;43:948–950.
   PubMed Web of Science ®Google Scholar
• Levy MJ, Thompson GB, Topazian MD, et al. US-guided ethanol ablation of insulinomas: a new treatment option. Gastrointest Endosc. 2012;75:200–206.
   PubMed Web of Science ®Google Scholar
• Qin SY, Lu XP, Jiang HX. EUS-guided ethanol ablation of insulinomas: case series and literature review. Medicine (Baltimore). 2014;93:e85.
   PubMed Web of Science ®Google Scholar
• Muscatiello N, Salcuni A, Macarini L, et al. Treatment of a pancreatic endocrine tumor by ethanol injection guided by endoscopic ultrasound. Endoscopy. 2008;40(Suppl 2):E258–E259.
   PubMed Web of Science ®Google Scholar
• Park DH, Choi JH, Oh D, et al. Endoscopic ultrasonography-guided ethanol ablation for small pancreatic neuroendocrine tumors: results of a pilot study. Clin Endosc. 2015;48:158–164.
   PubMed Web of Science ®Google Scholar
• Waung JA, Todd JF, Keane MG, et al. Successful management of a sporadic pancreatic insulinoma by endoscopic ultrasound-guided radiofrequency ablation. Endoscopy. 2016;48(Suppl 1):E144–E145.
   Google Scholar
• Broder MS, Beenhouwer D, Strosberg JR, et al. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review. World J Gastroenterol. 2015;21:1945–1955.
   PubMed Web of Science ®Google Scholar
• Khan MS, El-Khouly F, Davies P, et al. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Aliment Pharmacol Ther. 2011;34:235–242.
   PubMed Web of Science ®Google Scholar
• Ruszniewski P, Valle JW, Lombard-Bohas C, et al. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: an international observational study. Dig Liver Dis. 2016;48:552–558.
   PubMedGoogle Scholar
• Strosberg JR, Benson AB, Huynh L, et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014;19:930–936.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Wolin EM, Liyanage N, et al. Evaluation ofLanreotide Depot/Autogel efficacy and safety as a carcinoid syndrome treatment (elect): A randomized, double-blind placebo-controlled study. Endocr Pract. 2016; doi: 10.4158/EP151172.OR. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Vezzosi D, Bennet A, Courbon F, et al. Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism. Clin Endocrinol (Oxf). 2008;68:904–911.
   PubMed Web of Science ®Google Scholar
• Koelz A, Kraenzlin M, Gyr K, et al. Escape of the response to a long-acting somatostatin analogue (SMS 201-995) in patients with VIPoma. Gastroenterology. 1987;92(2):527–531.
   PubMed Web of Science ®Google Scholar
• Maton PN, Gardner JD, Jensen RT. Use of the long-acting somatostatin analog, SMS 201-995 in patients with pancreatic islet cell tumors. Dig Dis Sci. 1989;34:28S–39S.
   Google Scholar
• Peng SY, Li JT, Liu YB, et al. Diagnosis and treatment of VIPoma in China: (case report and 31 cases review) diagnosis and treatment of VIPoma. Pancreas. 2004;28:93–97.
   PubMed Web of Science ®Google Scholar
• Farley HA, Pommier RF. Treatment of neuroendocrine liver metastases. Surg Oncol Clin N Am. 2016;25:217–225.
   PubMed Web of Science ®Google Scholar
• Lesurtel M, Nagorney DM, Mazzaferro V, et al. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB (Oxford). 2015;17:17–22.
   PubMed Web of Science ®Google Scholar
• Khan MU, Morse M, Coleman RE. Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors. Q J Nucl Med Mol Imaging. 2008;52:441–454.
   PubMed Web of Science ®Google Scholar
• Taal BG, Hoefnagel CA, Valdes Olmos RA, et al. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol. 1996;14:1829–1838.
   PubMed Web of Science ®Google Scholar
• Bomanji JB, Wong W, Gaze MN, et al. Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy. Clin Oncol (R Coll Radiol). 2003;15:193–198.
   PubMed Web of Science ®Google Scholar
• Pathirana AA, Vinjamuri S, Byrne C, et al. (131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome. Eur J Surg Oncol. 2001;27:404–408.
   PubMed Web of Science ®Google Scholar
• Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer. 2004;101:1987–1993.
   PubMed Web of Science ®Google Scholar
• Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab. 2001;86:895–902.
   PubMed Web of Science ®Google Scholar
• Feitosa AC, Castro Junior DO, Rocha Filho J, et al. Spinal cord compression after radiolabeled metaiodobenzylguanidine analogue therapy in advanced malignant insulinoma. Arch Endocrinol Metab. 2015;59:186–189.
   PubMed Web of Science ®Google Scholar
• Pasieka JL, McEwan AJ, Rorstad O. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery. 2004;136:1218–1226.
   PubMed Web of Science ®Google Scholar
• Gelhorn HL, Kulke MH, O’Dorisio T, et al. Patient-reported symptom experiences in patients with carcinoid syndrome after participation in a study of telotristat etiprate: a qualitative interview approach. Clin Ther. 2016;38:759–768.
   PubMed Web of Science ®Google Scholar
• Pavel M, Wiedenmann B, Caplin M, et al. Telotristat etiprate produces clinical and biochemical responses in patients with carcinoid syndrome: results of a phase 2, multicenter, opern-lable, serial-ascending study. In ENETs 2013 meeting abstracts(M4). 2013. p. 153. Ref Type: Abstract.
   Google Scholar
• Molina-Cerrillo J, Alonso-Gordoa T, Martinez-Saez O, et al. Inhibition of peripheral synthesis of serotonin as a new target in neuroendocrine tumors. Oncologist. 2016;21:701–707.
   PubMed Web of Science ®Google Scholar
• Horsch D, Kulke M, Caplin M, et al. Efficacy and safety of Telostristat Etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: analysis of ongoing TELESTAR extension period. In: Abstract book of 13th Annual ENET Conference; 2016 Mar 9–11; Barcelona (Spain); 2016. p. 245. Ref Type: Abstract.
   Google Scholar
• Pavel M, Horsch D, Caplin M, et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab. 2015;100:1511–1519.
   PubMed Web of Science ®Google Scholar
• Pavel M, Horsch D, Anthony L, et al. Patient interviews in TELESTAR, a Phase 3 study of Telotristat etiprate, report meaningful improvement in carcnoid syndrome. In: Abstract book of 13th annual ENET conference; 2016 Mar 9–11; Barcelona (Spain); 2016. p. 247. Ref Type: Abstract.
   Google Scholar
• Zacks J, Lavine R, Ratner L, et al. Telostristat etiprate appears to halt carcinoid heart disease. In: Abstract book of 13th Annual ENET Conference; 2016 Mar 9–11; Barcelona (Spain); 2016. p. 248. Ref Type: Abstract.
   Google Scholar
• Baldelli R, Barnabei A, Rizza L, et al. Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front Endocrinol (Lausanne). 2014;5:7.
   PubMed Web of Science ®Google Scholar
• Cives M, Kunz PL, Morse B, et al. Phase II clinical trial of pasireotide LAR in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer. 2015;22:1–9.
   PubMed Web of Science ®Google Scholar
• Kvols LK, Oberg KE, O’Dorisio TM, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer. 2012;19:657–666.
   PubMed Web of Science ®Google Scholar
• Wemeau JL. Therapeutic innovations in endocrine diseases - Part 4: pasireotide: long-acting release somatostatin analogue. Presse Med. 2016;45:e217–e220.
   Google Scholar
• Wolin EM, Jarzab B, Eriksson B, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther. 2015;9:5075–5086.
   PubMed Web of Science ®Google Scholar
• Tirosh A, Stemmer SM, Solomonov E, et al. Pasireotide for malignant insulinoma. Hormones (Athens). 2016;15:271–276.
   PubMedGoogle Scholar
• Quinn TJ, Yuan Z, Adem A, et al. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model. Surgery. 2012;152:1068–1077.
   PubMed Web of Science ®Google Scholar
• Wolin EM, Hu K, Hughes G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study. Cancer Chemother Pharmacol. 2013;72:387–395.
   PubMed Web of Science ®Google Scholar
• Henry RR, Ciaraldi TP, Armstrong D, et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98:3446–3453.
   PubMed Web of Science ®Google Scholar
• Kamp K, Alwani RA, Korpershoek E, et al. Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors. Eur J Endocrinol. 2016;174:271–280.
   PubMed Web of Science ®Google Scholar
• Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol. 1999;17:615–630.
   PubMed Web of Science ®Google Scholar
• Ambrogio AG, Cavagnini F. Role of “old” pharmacological agents in the treatment of Cushing’s syndrome. J Endocrinol Invest. 2016; 39:957–965.
   PubMed Web of Science ®Google Scholar
• Creemers SG, Hofland LJ, Lamberts SW, et al. Cushing’s syndrome: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother. 2015;16:1829–1844.
   PubMed Web of Science ®Google Scholar
• Lacroix A, Feelders RA, Stratakis CA, et al. Cushing’s syndrome. Lancet. 2015;386:913–927.
   PubMed Web of Science ®Google Scholar
• Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:2807–2831.
   PubMed Web of Science ®Google Scholar
• Moraitis AG, Auchus RJ. Mifepristone improves octreotide efficacy in resistant ectopic Cushing’s syndrome. Case Rep Endocrinol. 2016;2016:8453801.
   PubMedGoogle Scholar
• Jensen RT, Berna MJ, Bingham MD, et al. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management and controversies. Cancer. 2008;113(7):suppl):1807-1843.
   Web of Science ®Google Scholar
• Benya RV, Metz DC, Venzon DJ, et al. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type 1. Am J Med. 1994;97:436–444.
   PubMed Web of Science ®Google Scholar
• Gibril F, Doppman JL, Reynolds JC, et al. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management. J Clin Oncol. 1998;16:1040–1053.
   PubMed Web of Science ®Google Scholar
• Von Schrenck T, Howard JM, Doppman JL, et al. Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology. 1988;94:1326–1334.
   PubMed Web of Science ®Google Scholar
• Krudy AG, Doppman JL, Jensen RT, et al. Localization of islet cell tumors by dynamic CT: comparison with plain CT, arteriography, sonography and venous sampling. Am J Roentgenol. 1984;143:585–589.
   PubMed Web of Science ®Google Scholar
• Thom AK, Norton JA, Axiotis CA, et al. Location, incidence and malignant potential of duodenal gastrinomas. Surgery. 1991;110:1086–1093.
   PubMed Web of Science ®Google Scholar
• Ito T, Jensen RT. Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies. Int J Endocr Oncol. 2016;3:53–66.
   PubMed Web of Science ®Google Scholar
• Doppman JL, Miller DL, Chang R, et al. Gastrinomas: localization by means of selective intraarterial injection of secretin. Radiology. 1990;174:25–29.
   PubMed Web of Science ®Google Scholar
• Cherner JA, Doppman JL, Norton JA, et al. Selective venous sampling for gastrin to localize gastrinomas. A prospective study. Ann Intern Med. 1986;105:841–847.
   PubMed Web of Science ®Google Scholar
• Pavel M, Baudin E, Couvelard A, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157–176.
   PubMed Web of Science ®Google Scholar
• Pokuri VK, Fong MK, Iyer R. Octreotide and lanreotide in gastroenteropancreatic neuroendocrine tumors. Curr Oncol Rep. 2016;18:7.
   PubMed Web of Science ®Google Scholar
• Patel C, Mathur M, Escarcega RO, et al. Carcinoid heart disease: current understanding and future directions. Am Heart J. 2014;167:789–795.
   PubMed Web of Science ®Google Scholar
• Bushnell DL Jr, O’Dorisio TM, O’Dorisio MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010;28:1652–1659.
   PubMed Web of Science ®Google Scholar
• Gu P, Wu J, Newman E, et al. Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin. Int J Hepatol. 2012;2012(Article ID131659):1–8.
   Google Scholar
• King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008;113:921–929.
   PubMed Web of Science ®Google Scholar
• Paprottka PM, Hoffmann RT, Haug A, et al. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol. 2012;35:334–342.
   PubMed Web of Science ®Google Scholar
• Cazzato RL, Garnon J, Ramamurthy N, et al. 18F-FDOPA PET/CT-guided radiofrequency ablation of liver metastases from neuroendocrine tumours: technical note on a preliminary experience. Cardiovasc Intervent Radiol. 2016;39:1315–1321.
   Web of Science ®Google Scholar
• Chadha MK, Lombardo J, Mashtare T, et al. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer Res. 2009;29:4127–4130.
   PubMed Web of Science ®Google Scholar
• Anthony L, Vinik AI. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period. Pancreas. 2011;40:987–994.
   PubMed Web of Science ®Google Scholar
• Ferolla P, Faggiano A, Grimaldi F, et al. Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. J Endocrinol Invest. 2012;35:326–331.
   PubMed Web of Science ®Google Scholar
• McEntee GP, Nagorney DM, Kvols LK, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091–1096.
   PubMed Web of Science ®Google Scholar
• Que FG, Sarmiento JM, Nagorney DM. Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Adv Exp Med Biol. 2006;574:43–56.
   PubMed Web of Science ®Google Scholar
• Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29–37.
   PubMed Web of Science ®Google Scholar
• Farley HA, Pommier RF. Surgical treatment of small bowel neuroendocrine tumors. Hematol Oncol Clin North Am. 2016;30:49–61.
   PubMed Web of Science ®Google Scholar
• Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg. 2002;26:985–990.
   PubMed Web of Science ®Google Scholar
• Ezziddin S, Sabet A, Logvinski T, et al. Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors. J Nucl Med. 2013;54:2032–2038.
   PubMed Web of Science ®Google Scholar
• Grunwald F, Ezziddin S. 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. Semin Nucl Med. 2010;40:153–163.
   PubMed Web of Science ®Google Scholar
• Mulholland N, Chakravartty R, Devlin L, et al. Long-term outcomes of (131)Iodine MIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders. Eur J Nucl Med Mol Imaging. 2015;42:2002–2012.
   PubMed Web of Science ®Google Scholar
• Buscombe JR, Cwikla J, Caplin ME, et al. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl Med Commun. 2005;26:969–976.
   PubMed Web of Science ®Google Scholar
• Usukura M, Yoneda T, Oda N, et al. Medical treatment of benign insulinoma using octreotide LAR: a case report. Endocr J. 2007;54:95–101.
   PubMed Web of Science ®Google Scholar
• Vezzosi D, Bennet A, Rochaix P, et al. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol. 2005;152:757–767.
   PubMed Web of Science ®Google Scholar
• Baudin E, Caron P, Lombard-Bohas C, et al. Malignant insulinoma: recommendations for characterisation and treatment. Ann Endocrinol (Paris). 2013;74:523–533.
   PubMed Web of Science ®Google Scholar
• Stehouwer CD, Lems WF, Fischer HR, et al. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). Acta Endocrinol (Copenh). 1989;121:34–40.
   PubMedGoogle Scholar
• Healy ML, Dawson SJ, Murray RM, et al. Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma. Intern Med J. 2007;37:406–409.
   PubMed Web of Science ®Google Scholar
• Ong GS, Henley DE, Hurley D, et al. Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. Eur J Endocrinol. 2010;162:1001–1008.
   PubMed Web of Science ®Google Scholar
• Scharf M, Mueller D, Koenig U, et al. Management of a metastasized high grade insulinoma (G3) with refractory hypoglycemia: case report and review of the literature. Pancreatology. 2014;14:542–545.
   PubMed Web of Science ®Google Scholar
• Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190:432–445.
   PubMed Web of Science ®Google Scholar
• Yao KA, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001;130:677–682.
   PubMed Web of Science ®Google Scholar
• Chen OT, Dojki FK, Weber SM, et al. Percutaneous microwave ablation of an insulinoma in a patient with refractory symptomatic hypoglycemia. J Gastrointest Surg. 2015;19:1378–1381.
   PubMed Web of Science ®Google Scholar
• Rossi S, Viera FT, Ghittoni G, et al. Radiofrequency ablation of pancreatic neuroendocrine tumors: a pilot study of feasibility, efficacy, and safety. Pancreas. 2014;43:938–945.
   PubMed Web of Science ®Google Scholar
• Limmer S, Huppert PE, Juette V, et al. Radiofrequency ablation of solitary pancreatic insulinoma in a patient with episodes of severe hypoglycemia. Eur J Gastroenterol Hepatol. 2009;21:1097–1101.
   PubMed Web of Science ®Google Scholar
• Scott A, Hinwood D, Donnelly R. Radio-frequency ablation for symptom control in a patient with metastatic pancreatic insulinoma. Clin Endocrinol (Oxf). 2002;56:557–559.
   PubMed Web of Science ®Google Scholar
• MacFarlane MP, Fraker DL, Alexander HR, et al. A prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia-Type 1. Surgery. 1995;118:973–980.
   PubMed Web of Science ®Google Scholar
• Termanini B, Gibril F, Sutliff VE III, et al. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med. 1998;104:422–430.
   PubMed Web of Science ®Google Scholar
• Said R, O’Reilly EM, Blumgart L, et al. Pancreatic islet cell carcinoma presenting with concurrent Cushing’s and Zollinger-Ellison syndromes: case series and literature review. Eur J Gastroenterol Hepatol. 2010;22:246–252.
   PubMed Web of Science ®Google Scholar
• Ellison EC. Zollinger-Ellison syndrome: a personal perspective. Am Surg. 2008;74:563–571.
   PubMed Web of Science ®Google Scholar
• Eriksson B, Renstrup J, Imam H, et al. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol. 1997;8:1041–1044.
   PubMed Web of Science ®Google Scholar
• Case CC, Wirfel K, Vassilopoulou-Sellin R. Vasoactive intestinal polypeptide-secreting tumor (VIPoma) with liver metastases: dramatic and durable symptomatic benefit from hepatic artery embolization, a case report. Med Oncol. 2002;19:181–187.
   PubMed Web of Science ®Google Scholar
• Shaib W, Mitchell K, Saif MW. Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma. Yale J Biol Med. 2010;83:27–33.
   PubMedGoogle Scholar
• Abu-Zaid A, Azzam A, Abudan Z, et al. Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male. Hematol Oncol Stem Cell Ther. 2014;7:109–115.
   PubMedGoogle Scholar
• Haiqing W, Jiayin Y, Jian Y, et al. Intractable and dramatic diarrhea in liver transplantation recipient with vasoactive intestinal peptide-producing tumor after split liver transplantation: a case report. Transplant Proc. 2015;47:171–173.
   PubMed Web of Science ®Google Scholar
• Moug SJ, Leen E, Horgan PG, et al. Radiofrequency ablation has a valuable therapeutic role in metastatic VIPoma. Pancreatology. 2006;6:155–159.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhou L, Liu Y, et al. Surgical resection of vasoactive intestinal peptideoma with hepatic metastasis aids symptom palliation: A case report. Exp Ther Med. 2016;11:783–787.
   PubMed Web of Science ®Google Scholar
• Amikura K, Alexander HR, Norton JA, et al. The role of surgery in the management of ACTH-producing islet cell tumors of the pancreas. Surgery. 1995;118:1125–1130.
   PubMed Web of Science ®Google Scholar
• Druce M, Rockall A, Grossman AB. Fibrosis and carcinoid syndrome: from causation to future therapy. Nat Rev Endocrinol. 2009;5:276–283.
   PubMed Web of Science ®Google Scholar
• Cunningham JL, Janson ET, Agarwal S, et al. Tachykinins in endocrine tumors and the carcinoid syndrome. Eur J Endocrinol. 2008;159:275–282.
   PubMed Web of Science ®Google Scholar
• Doppman JL, Nieman L, Miller DL, et al. Ectopic adrenocorticotropic hormone syndrome: localization studies in 28 patients [published erratum appears in Radiology 1989 Oct;173(1):286]. Radiology. 1989;172:115–124.
   PubMed Web of Science ®Google Scholar
• Alexandraki KI, Grossman AB. Therapeutic strategies for the treatment of severe Cushing’s syndrome. Drugs. 2016;76:447–458.
   PubMed Web of Science ®Google Scholar